CA2240271C - Utilisation de certains composes d'isoquinolinesulfonyle dans le traitement de glaucomes et d'ischemies oculaires - Google Patents

Utilisation de certains composes d'isoquinolinesulfonyle dans le traitement de glaucomes et d'ischemies oculaires Download PDF

Info

Publication number
CA2240271C
CA2240271C CA002240271A CA2240271A CA2240271C CA 2240271 C CA2240271 C CA 2240271C CA 002240271 A CA002240271 A CA 002240271A CA 2240271 A CA2240271 A CA 2240271A CA 2240271 C CA2240271 C CA 2240271C
Authority
CA
Canada
Prior art keywords
composition
compound
group
carbon atoms
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002240271A
Other languages
English (en)
Other versions
CA2240271A1 (fr
Inventor
Michael A. Kapin
Louis M. Desantis, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Priority claimed from PCT/US1996/020197 external-priority patent/WO1997023222A1/fr
Publication of CA2240271A1 publication Critical patent/CA2240271A1/fr
Application granted granted Critical
Publication of CA2240271C publication Critical patent/CA2240271C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Cette invention concerne des composés d'isoquinolinesulfonyle, lesquels sont utilisés dans des compositions ophtalmiques afin de traiter des glaucomes ou d'autres troubles oculaires d'origine ischémique, tel que des rétinopathies ou des neuropathies optiques. Ces composés permettent d'effectuer une vasodilatation des vaisseaux sanguins oculaires, d'abaisser la pression intra-oculaire, et de prévenir ou réduire la progression d'une perte du champ visuel.
CA002240271A 1995-12-21 1996-12-20 Utilisation de certains composes d'isoquinolinesulfonyle dans le traitement de glaucomes et d'ischemies oculaires Expired - Fee Related CA2240271C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US935195P 1995-12-21 1995-12-21
US60/009,351 1995-12-21
PCT/US1996/020197 WO1997023222A1 (fr) 1995-12-21 1996-12-20 Utilisation de certains composes d'isoquinolinesulfonyle dans le traitement de glaucomes et d'ischemies oculaires

Publications (2)

Publication Number Publication Date
CA2240271A1 CA2240271A1 (fr) 1997-07-03
CA2240271C true CA2240271C (fr) 2005-12-13

Family

ID=35517628

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002240271A Expired - Fee Related CA2240271C (fr) 1995-12-21 1996-12-20 Utilisation de certains composes d'isoquinolinesulfonyle dans le traitement de glaucomes et d'ischemies oculaires

Country Status (1)

Country Link
CA (1) CA2240271C (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232292B2 (en) 2007-07-02 2012-07-31 Asahi Kasei Pharma Corporation Sulfonamide compound and crystal thereof
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083175A1 (fr) 2001-04-11 2002-10-24 Senju Pharmaceutical Co., Ltd. Agents ameliorant la fonction visuelle
EP2130828A4 (fr) 2007-02-28 2010-12-29 Asahi Kasei Pharma Corp Dérivé de sulfonamide

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
US8232292B2 (en) 2007-07-02 2012-07-31 Asahi Kasei Pharma Corporation Sulfonamide compound and crystal thereof
US8664243B2 (en) 2007-07-02 2014-03-04 Asahi Kasei Pharma Corporation Sulfonamide compound and crystal thereof

Also Published As

Publication number Publication date
CA2240271A1 (fr) 1997-07-03

Similar Documents

Publication Publication Date Title
US6271224B1 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
US5605922A (en) Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
EP0639986A1 (fr) Compositions ophtalmiques a usage local contenant une combinaison d'antagonistes du calcium et d'agents antiglaucome
EP0686393A1 (fr) Préparations ophtalmiques contenant du sarpognelate pour réduire la pression intraoculaire
US5438060A (en) Method of reducing elevated intraocular pressure
US5049587A (en) Ophthalmic solution for intraocular pressure adjustment
US5883108A (en) Combination therapy for treating glaucoma
CA2240271C (fr) Utilisation de certains composes d'isoquinolinesulfonyle dans le traitement de glaucomes et d'ischemies oculaires
Chiou Ocular hypotensive actions of haloperidol, a dopaminergic antagonist
WO2019131901A1 (fr) Préparation pharmaceutique contenant un composé d'acide pyridylaminoacétique
US5308849A (en) Method of reducing elevated intraocular pressure
EP0728480A1 (fr) Utilisation d'ifenprodil pour le traitement de la pression intraoculaire élevée
EP0375299A1 (fr) Mélanges d'inhibiteurs ACE et CA pour le traitement du glaucome
TW200301128A (en) Ophthalmic composition for the treatment of glaucoma, ocular hypertension, ocular ischemia and related disorders
US5563171A (en) Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists
US5428030A (en) Method of reducing elevated intraocular pressure
AU2006200143B2 (en) Combination therapy for lowering and controlling intraocular pressure
EP0375319A3 (fr) Utilisation des inhibiteurs de l'enzyme convertissant l'angiotensine dans le traitement du glaucome

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed